<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In two institutions in MÃ©xico, twelve patients were given a second allogeneic stem cell transplantation, using the "Mexican" non-myeloablative preparative regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Eight had a malignant condition (six <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, one <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and one <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>), eleven individuals were allografted twice from the same donor and in one case, cells from two different umbilical cords were used </plain></SENT>
<SENT sid="2" pm="."><plain>The median time to conduct the second allograft after the first one was 6 months (range 1-41) </plain></SENT>
<SENT sid="3" pm="."><plain>The five patients who failed to engraft after the first transplant failed also to engraft after the second one; <z:hpo ids='HP_0000001'>all</z:hpo> of them had been heavily transfused </plain></SENT>
<SENT sid="4" pm="."><plain>Only three patients were successfully rescued with the second transplant, two with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and one with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Seven patients are alive 10-41 months (median 35) after the second transplant, but only three (25%) remain disease-free </plain></SENT>
<SENT sid="6" pm="."><plain>The 52-month overall survival (SV) of the patients is 58%, whereas the median overall SV has not been reached, being above 52 months </plain></SENT>
<SENT sid="7" pm="."><plain>Conducting a second allograft may be useful to rescue some individuals relapsing after a first hematopoietic allotransplant </plain></SENT>
</text></document>